Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06915688

A Study Comparing Doxycycline and Levofloxacin for Treating COPD Exacerbations

This study will include patients with chronic obstructive pulmonary disease (COPD) who present with an acute exacerbation. Participants will be randomly assigned to receive either doxycycline or levofloxacin for 5 days. The aim is to compare how effective each antibiotic is in improving symptoms after 2 days of treatment.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

COPD Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

This randomized controlled trial will evaluate the effectiveness of two antibiotics-doxycycline (a tetracycline) and levofloxacin (a fluoroquinolone)-in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Participants will be assigned to one of the two treatment groups and will receive either doxycycline 100 mg twice daily or levofloxacin 500 mg once daily for 5 days. The primary outcome is clinical cure. This will be evaluated 2 days after completion of antibiotic therapy, based on symptom resolution and laboratory markers.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosed cases of COPD Exacerbation of COPD Able to provide Written consent No anti biotic taken with in past 4 weeks

Exclusion criteria

  • hypersensitivity to any drugs Pneumonia evidence on xray/ hrct chest Any other pulmonary condition e.g asthma Pregnancy/breast feeding Taking treatment for other active infections

Treatment and study plan

Doxycycline

Drug

Doxycycline will be given to COPD group 1

Levofloxacin

Drug

Levofloxacin given to copd patients

Primary outcomes

  1. Clinical Cure Rate

    Time frame: 7 days

    • A decrease in the respiratory rate by 20% from the baseline measurement.
    • Restoration of Oxygen saturation levels to within the range of 88-92% on room air.
    • CRP<10ng/ml
    • decrease in sputum quantity
    • reduction in body temperature below 99•F
    • TLC <11,000

Study contacts

Contact information is provided by the study sponsor or research team.

Amina Aslam, MBBS

CONTACT

[email protected]

+923024748021

Sponsors and collaborators

Lead sponsor

Amina Aslam

Other Gov

Registry information

Official study title

Comparison of Clinical Cure Rate of Doxycycline and Levofloxacin in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Acronym: DOLE-COPD

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 8, 2025
Registry last updated
Apr 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.